COVID-19 Stress Syndrome, COVID-19 Vaccine Adverse Reaction, COVID-19-Associated Thromboembolism, COVID-19 Post-Intensive Care Syndrome, COVID-19-Associated Stroke, COVID-19 Respiratory Infection
Conditions
Keywords
COVID-19, SARS-CoV-2, Low Density Lipoprotein Cholesterol, sebum, immune reflex, immunology, immune deficiency, immune regulation, detoxification
Brief summary
The study hypothesizes that SARS-CoV-2 vaccination poisoning hibernates in human host in Low Density Lipoprotein Cholesterol (LDL-C). The clinical trial is a follow-up from the intervention trial with NCT number NCT05711810. It tests the use of Atorvastatin Calcium Tablets for detoxification and prevention of blood acidification, and the use of the Chinese herb compounded Anti-Viral Granules for the detoxification in the endocrine system.
Interventions
COMBINATION_PRODUCTAtorvastatin Calcium Tablets
The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.
Sponsors
Yang I. Pachankis
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* People who received COVID-19 vaccinations, or experiencing long-COVID.
Exclusion criteria
* People with moderate and severe liver dysfunctions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Platelet Volume Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| Red cell Distribution Width Standard Deviation Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| Plateletcrit Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| Platelet Distribution Width Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| Total Cholesterol Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. It is hypothesized that total cholesterol levels indicate to the initial acidification for SARS-CoV-2 viral entry through vaccines with the degeneration of lipids. |
| Triglycerides Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. It is hypothesized that triglycerides levels indicate to the initial acidification for SARS-CoV-2 viral entry through vaccines. |
| HDL-C Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| LDL-C Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. It is hypothesized that SARS-CoV-2 hibernating viruses and viral proteins are hidden in the LDL-C. |
| Apolipoprotein A-I Change | 30 days | — |
| Apolipoproteina B Change | 30 days | — |
| Lipopoliproteina (a) Change | 30 days | — |
| Eosinophil Absolute Number Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| Eosinophil Percentage Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| Basophil Absolute Number Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| Basophil Percentage Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| Mean Corpuscular Volume Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| Mean Corpuscular Hemoglobin Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| Mean Corpuscular Hemoglobin Concentration Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
| Red cell Distribution Width Coefficient of Variation Change | 30 days | The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Systolic Blood Pressure Change | 4 hours | The blood pressure change will be compared with the baseline characteristics for observation on the risks of rebound to the previous intervention. Type I error testing defines Systolic & Diastolic Blood Pressure and heart rate as incremented. SBP variance indicates to infection activities. |
| Diastolic Blood Pressure Change | 4 hours | The blood pressure change will be compared with the baseline characteristics for observation on the risks of rebound to the previous intervention. Type I error testing defines Systolic & Diastolic Blood Pressure and heart rate as incremented. DBP variance indicates to immune attack activities. |
| Heart Rate Change | 4 hours | The blood pressure change will be compared with the baseline characteristics for observation on the risks of rebound to the previous intervention. Type I error testing defines Systolic & Diastolic Blood Pressure and heart rate as incremented. Heart rate variance indicates to immune responses. |
Countries
China
Outcome results
None listed